Gulick, Roy M., Fatkenheuer, Gerd, Burnside, Robert, Hardy, W. David, Nelson, Mark R., Goodrich, James, Mukwaya, Geoffrey, Portsmouth, Simon and Heera, Jayvant R. (2014). Five-Year Safety Evaluation of Maraviroc in HIV-1-Infected Treatment-Experienced Patients. JAIDS, 65 (1). S. 78 - 82. PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS. ISSN 1077-9450

Full text not available from this repository.

Abstract

Background: Maraviroc is unique among approved antiretroviral drugs in targeting the host-cell chemokine coreceptor type-5 receptor. With its novel mechanism of action, we sought to describe the 5-year safety profile of maraviroc. Methods: Two large phase 3 studies of maraviroc enrolled HIV-infected treatment-experienced patients and followed them up for 5 or more years. Survival and selected clinical end points were identified and assessed. Results: A total of 938 enrolled patients received maraviroc-containing regimens. Rates of death and selected clinical events (eg, hepatic failure, malignancy, and myocardial infarction) were low during follow-up. Conclusions: Maraviroc was generally safe in treatment-experienced participants for >5 years.

Item Type: Journal Article
Creators:
CreatorsEmailORCIDORCID Put Code
Gulick, Roy M.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Fatkenheuer, GerdUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Burnside, RobertUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Hardy, W. DavidUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Nelson, Mark R.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Goodrich, JamesUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Mukwaya, GeoffreyUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Portsmouth, SimonUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Heera, Jayvant R.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
URN: urn:nbn:de:hbz:38-450313
DOI: 10.1097/QAI.0b013e3182a7a97a
Journal or Publication Title: JAIDS
Volume: 65
Number: 1
Page Range: S. 78 - 82
Date: 2014
Publisher: LIPPINCOTT WILLIAMS & WILKINS
Place of Publication: PHILADELPHIA
ISSN: 1077-9450
Language: English
Faculty: Unspecified
Divisions: Unspecified
Subjects: no entry
Uncontrolled Keywords:
KeywordsLanguage
HIV-1 INFECTION; CCR5 ANTAGONIST; EFFICACY; VICRIVIROC; THERAPYMultiple languages
Immunology; Infectious DiseasesMultiple languages
URI: http://kups.ub.uni-koeln.de/id/eprint/45031

Downloads

Downloads per month over past year

Altmetric

Export

Actions (login required)

View Item View Item